BMO Capital analyst Do Kim initiated with a Market Perform rating and $322 price target. Kim called Biogen fairly valued, and suggested remaining on the sidelines until “meaningful overhangs lift on the stock, including results from a Phase 2 tauopothy trial evaluating BIIB092 in progressive supranuclear palsy and Phase 3 trials evaluating aducanumab in early Alzheimer’s disease, expected 2H/19 and 1H/20, respectively.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.